Differential effect of the immunomodulator AS101 on B7-1 and B7-2 costimulatory molecules: Role in the antitumoral effects of AS101

Journal of Immunology

Volumn 157, Issue 2, 1996, Pages 589-597

  Kalechman, Yona ^a   Sredni, Benjamin ^a  

^a BAR ILAN UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

AMMONIUM TRICHLORO(DIOXYETHYLENE O,O')TELLURATE; B7 ANTIGEN; CD28 ANTIGEN; CD86 ANTIGEN; GAMMA INTERFERON; IMMUNOMODULATING AGENT; INTERLEUKIN 2; INTERLEUKIN 4; LIGAND; LIPOPOLYSACCHARIDE; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; OKT 3;

ACCESSORY CELL; ADVANCED CANCER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ARTICLE; CANCER TRANSPLANTATION; CONTROLLED STUDY; DRUG EFFECT; IMMUNOMODULATION; INTRAPERITONEAL DRUG ADMINISTRATION; LEWIS CARCINOMA; LIGAND BINDING; LYMPHOCYTE PROLIFERATION; MALE; MOUSE; NONHUMAN; PERITONEUM MACROPHAGE; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD; ANTIGENS, CD3; ANTIGENS, CD80; ANTIGENS, CD86; ANTINEOPLASTIC AGENTS; ETHYLENES; INTERLEUKIN-10; INTERLEUKIN-2; LYMPHOCYTE ACTIVATION; MACROPHAGE ACTIVATION; MACROPHAGES, PERITONEAL; MALE; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; T-LYMPHOCYTES; TELLURIUM; UP-REGULATION;

EID: 0029982870     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (49)

1. Schwartz, R. H. 1990. A cell culture model for T lymphocyte clonal anergy. Science 248:1349.
2. June, C. H., J. A. Ledbetler, M. M. Gillespie, T. Lindsten, and C. B. Thompson. 1987. T-cell proliferation involving the CD28 pathway is associated with cyclosporine-resistant interleukin 2 gene expression. Mol. Cell. Biol. 7:4472.
3. Freeman, G. J., G. S. Gray, C. D. Gimmi, D. B. Lombard, L. J. Zhou, M. White, J. D. Fingeroth, J. G. Gribben, and L. M. Nadler. 1991. Structure, expression, and T cell costimulatory activity of the murine homologue of the human B lymphocyte activation antigen B7. J. Exp. Med. 174:625.
4. Ramsdell, F., and B. J. Fowlkes. Clonal deletion versus clonal anergy: the role of the thymus in inducing self tolerance. 1990. Science 248:1342.
5. Weaver, C. T., and E. R. Unanue. 1990. The costimulatory function of antigen-presenting cells. Immunol. Today 11:49.
6. June, C. H., J. A. Ledbetter, P. S. Linsley, and C. B. Thompson. 1990. Role of the CD28 receptor. Immunol. Today 11:211.
7. Linsley, P. S., W. Brady, M. Urnes, L. S. Grosmaire, N. K. Damle, and J. A. Ledbetter. 1991. CTLA-4 is a second receptor for the B cell activation antigen B7. J. Exp. Med. 174:561.
8. Gimmi, C. D., G. J. Freeman, J. G. Gribben, G. Gray, and L. M. Nadler. 1993. Human T cell clonal anergy is induced by antigen presentation in the absence of B7 costimulation. Proc. Natl. Acad. Sci. 90:6586.
9. Sredni, B., R. R. Caspi, A. Klein, Y. Kalechman, Y. Danzinger, M. Ben Ya'akov, T. Tamari, F. Shalit, and M. Albeck. 1987. A new immunomodulating compound (AS101) with potential therapeutic application. Nature 330:173.
10. Shani A., T. Tichler, R. Catane, M. Gurwith, L. A. Rozenszajn, A. Gezin, E. Levi, M. Schlesinger, Y. Kalechman, H. Michlin, F. Shalit, E. Engelsman, H. Farbstein, M. Farbstein, M. Albeck, and B. Sredni. 1990. The immunologic effects of AS101 in the treatment of cancer patients. Nat. Immun. Cell Growth Regul. 9:182.
11. Kalechman, Y., M. Albeck, M. Oron, D. Sobelman, M. Gurwith, S. N. Sehgal, and B. Sredni. 1990. The radioprotective effects of the immunomodulator AS101. J. Immunol. 145:1512.
12. Kalechman, Y., G. Lederer, M. Albeck, and B. Sredni. 1995. Effect of the immunomodulator AS101 on chemotherapy-induced multilineage myelosuppression, thrombocytopenia and erythropenia in mice. Exp. Hematol. 23:1358.
13. Sredni, B., Y. Kalechman, M. Albeck, O. Gross, D. Aurbach, P. Sharon, S. N. Sehgal, M. J. Gurwith, and H. Michlin. 1990. Cytokine secretion effected by synergism of the immunomodulator AS101 and the protein kinase-C inducer bryostatin. Immunology 70:473.
14. Kalechman, Y., A. Shani, S. Dovrat, J. K. Whisnant, K. Mettinger, M. Albeck, and B. Sredni. 1996. The antitumoral effect of the immunomodulator AS101 and paclitaxel (Taxol) in a murine model of lung adenocarcinoma. J. Immunol. 156: 1101.
15. Cohen, J. 1993. T cell shift: key to AIDS therapy? Science 262:175.
16. Ghosh, P., L. Komschlies, M. Cippitelli, D. L. Longo, J. Subleski, J. Ye, A. Sica, H. A. Young, R. H. Wiltrout, and A. C. Ochoa. 1995. Loss of T-helper 1 (Th1) population in the spleen of mice during progressive tumor growth. J. Natl. Cancer. Inst. 87:1478.
17. Heinzel, F. P., M. D. Sadick, B. J. Holaday, R. L. Coffman, and R. M. Locksley. 1989. Reciprocal expression of interferon-γ or interleukin 4 during the resolution or progression of murine leishmaniasis: evidence for expansion of distinct helper T cell subsets. J. Exp. Med. 169:59.
18. Trinchieri, G. 1993. Interleukin 12 and its role in the generation of Th1 cells. Immunol. Today 14:335.
19. Yoshimoto, T., and W. E. Paul. 1994. CD4-POS, NK1.1 POS T cells promptly produce interleukin 4 in response to in vivo challenge with anti-CD3. J. Exp. Med. 179:1285.
20. Azuma, M., D. Ito, H. Yagita, K. Okumura, J. H. Philips, L. L. Lanier, and C. Somoza. 1993. B70 antigen is a second ligand for CTLA-4 and CD28. Nature 366:76.
21. Freeman, G. J., J. G. Gribben, V. A. Boussiotis, J. W. Ng, V. A. Restivo, G. S. Lombard, and L. M. Nadler. 1993. Uncovering of functional alternative CTLA-4 counter-receptor in B7-deficient mice. Science 262:907.
22. Kuchroo, V. K., M. P. Das, J. A. Brown, A. M. Ranger, S. S. Zamvil, R. A. Sobel, H. L. Weiner, N. Nabavi, and L. H. Glimcher. B7-1 and B7-2 costimulatory molecules activate differentially the Th1/Th2 developmental pathways: application to autoimmune disease therapy. 1995. Cell 80:707.
23. Ding, L., P. S. Linsley, L. Y. Huang, R. N. Germain, and E. M. Shevach. 1993. IL-10 inhibits macrophage costimulatory activity by selectively inhibiting the up-regulation of B7 expression. J. Immunol. 15:1224.
24. Fiorentino, D. F., M. W. Bond, and T. R. Mosmann. 1989. Two types of mouse T helper cells. IV. Th2 clones secrete a factor that inhibits cytokine production by Th1 clones. J. Exp. Med. 170:2081.
25. Fiorentino, D. F., A. Zlolnick, P. Vieira, T. R. Mosmann, M. Howard, K. W. Moore, and A. O'Garra. 1991. IL-10 acts on the antigen-presenting cell to inhibit cytokine production by Th1 cells. J. Immunol. 146:3444.
26. Sredni B., M. Albeck, T. Tichler, A. Shani, J. Shapira, I. Bruderman, R. Catane, B. Kaufman, and Y. Kalechamn. 1995. Bone marrow sparing and prevention of alopecia by AS101 in NSCL cancer patients treated with carboplatin and VP-16. J. Clin. Oncol. 13:2342.
27. Hardni, F. A., J. G. McArthur, J. A. Gross, D. H. Ranlet, and J. P. Allison. 1992. CD28-mediated signalling co-stimulates murine T cells and prevents induction of anergy in T-cell clones. Nature 356:607.
28. Turka, L. A., P. S. Linsley, H. Lin, W. Brady, J. M. Leiden, R. Wei, M. L. Gibson, X. Zhen, S. Myrdal, D. Gordon, T. Bailey, S. F. Bolling, and C. B. Thompson. 1992. T-cell activation by the CD28 ligand B7 is required for cardiac allograft rejection in vivo. Proc. Natl. Acad. Sci. USA 89:11102.
29. Sayegh, M. H., E. Akalin, W. W. Hancock, M. E. Russell, C. B. Carpenter, P. S. Linsley, and L. A. Turka. 1995. CD28-B7 blockade after alloantigen challenge in vivo inhibits ThI cytokines but spares Th2. J. Exp. Med. 181:1869.
30. Lenschow, D. J., Y. Zeng, J. R. Thistlethwaite, A. Montag, W. Brady, M. G. Gibson, P. S. Linsley, and J. A. Bluestone. 1992. Long-term survival of xenogeneic pancreatic islet grafts induced by CTLA4Ig. Science 257:789.
31. + T cells by B7-transfected melanoma cells. Science 259:368.
32. Chen, L., P. McGowan, S. Ashe, J. Johnston, Y. Li, I. Hellstrom, and K. E. Hellstrom. 1994. Tumor immunogenicity determines the effect of B7 costimulation on T cell-mediated tumor immunity. J. Exp. Med. 179:523.
33. Schwartz, R. H. 1992. Costimulation of T lymphocytes: the role of CD28, CTLA-4, and B7/BB1 in IL-2 production and immunotherapy. Cell 71:1065.
34. Chen, C., and N. Nabavi. 1994. In vitro induction of T cell anergy by blocking B7 and early T cell costimulatory molecule ETC-1/B7-2. Immunity 1:147.
35. Prabhu Das, M. R., S. S. Zamvil, F., Borriello, H. L. Weiner, A. H. Sharpe, and V. K. Kuchroo. 1995. Reciprocal expression of costimulatory molecules B7-1 and B7-2 on murine T cells following activation. Eur. J. Immunol. 25:207.
36. Hathcock, K. S., G. Laszlo, C. Pucillo, P. Linsley, and R. J. Hodes. 1994. Comparative analysis of B7-1 and B7-2 costimulatory ligands: expression and function. J. Exp. Med. 180:631.
37. Lanier, L. L., S. O'Fallon, C. Somoza, J. H. Philips, P. S. Linsley, K. Okumura, D. Ito, and M. Azuma. 1995. CD80(B7) and CD86(B70) provide similar costimulatory signals for T cell proliferation, cytokine production, and generation of CTL. J. Immunol. 154:97.
38. + T cells and induce similar patterns of cytokine secretion in vitro. Int. Immunol. 7:891.
39. Jenkins, M. K., C. A. Chen, G. Jung, L. Mueller, and R. H. Schwartz. 1990. Inhibition of antigen-specific proliferation of type 1 murine T cell clones after stimulation with immobilized anti-CD3 monoclonal antibody. J. Immunol. 144: 16.
40. Williams, M., E., A. H. Lichtman, and A. K. Abbas. 1990. anti-CD3 antibody induces unresponsiveness to IL-2 in Th1 clones but not in Th2 clones. J. Immunol. 144:1208.
41. Freeman, G. J., V. A. Boussiotis, A. Anumanthan, G. M. Bernstein, X. Y. Ke, P. D. Rennert, G. S. Gray, J. G. Gribben, and L. M. Nadler. 1995. B7-1 and B7-2 do not deliver identical costimulatory signals, since B7-2 but not B7-1 preferentially costimulates the initial production of IL-4. Immunity 2:523.
42. Thompson, C. B. 1995. Distinct roles for the costimulatory ligands B7-1 and B7-2 in T helper cell differentiation? Cell 81:979.
43. Blueslone, J. A. 1995. New perspectives of CD28-B7-mediated T cell costimulation. Immunity 2:555.
44. ras. J. Exp. Med. 180:1067.
45. Murphy, E. E., G. Terres, S. E. Macatonia, C. S. Itseih, J. Mattson, L. Lanier, M. Wysocka, G. Trinchieri, K. Murphy, and A. O'Garra. 1994. B7 and interleukin 12 cooperate for proliferation and IFN-γ production by mouse T helper clones that are unresponsive to B7 costimulation. J. Exp. Med. 180:223.
46. Sredni, B., R. R. Caspi, A. Klein, Y. Kalechman, Y. Danzinger, M. Ben Ya'akov, T. Tamari, F. Shalit, and M. Albeck. 1987. A new immunomodulating compound (AS101) with potential therapeutic application. Nature 330:173.
47. Sredni B., Y. Kalechman, F. Shalit, and M. Albeck. 1990. Synergism between AS101 and PMA in lymphokine production. Immunology 69:110.
48. Sredni B., Y. Kalechman, M. Albeck, O. Gross, D. Aurbach, P. Sharon, S. N. Sehgal, M. J. Gurwith, and H. Michlin. 1990. Cytokine secretion effected by synergism of the immunomodulator AS101 and the protein kinase C inducer bryostatin. Immunology 70:473.
49. Yamamura, M., R. L. Modlin, J. D. Ohmen, and R. L. Moy. 1993. Local expression of anti-inflammatory cytokines in cancer. J. Clin. Invest. 91:1005.